GnRH receptors expressed in cancer cells, and associated with antitumor activity, are now considered as an interesting molecular target for a new targeted therapeutic approach based on cytotoxic GnRH bioconjugates, compounds in which a GnRH derivative peptide is covalently linked to a cytotoxic drug. Here, GNRH1 is linked to cancer.